In the current study, we found no evidence of the BRAF, KRAS, NRAS, or PIK3CA mutations in rectal carcinoid tumors, suggesting that neither the RAS/RAF/MEK/ERK pathway nor the PI3K/AKT pathway were associated with tumorigenesis and disease progression in those tumors. This evidence concerns the gene BRAF and rectal neuroendocrine tumor G1.